Somatostatin and Alzheimer's disease

One of the most consistent neurochemical deficits in Alzheimer's disease is a reduction in cortical somatostatin concentrations. The probability of a predominant regulatory change is heightened by the finding that 90% of somatostatin positive nonpyramidal neurons are also positive for NADPH, an...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: Vécsei László
Klivényi Péter
Dokumentumtípus: Cikk
Megjelent: 1995
Sorozat:ARCHIVES OF GERONTOLOGY AND GERIATRICS 21
doi:10.1016/0167-4943(95)00640-7

mtmt:1032275
Online Access:http://publicatio.bibl.u-szeged.hu/10549
LEADER 01789nab a2200217 i 4500
001 publ10549
005 20221027141649.0
008 170215s1995 hu o 0|| zxx d
022 |a 0167-4943 
024 7 |a 10.1016/0167-4943(95)00640-7  |2 doi 
024 7 |a 1032275  |2 mtmt 
040 |a SZTE Publicatio Repozitórium  |b hun 
041 |a zxx 
100 1 |a Vécsei László 
245 1 0 |a Somatostatin and Alzheimer's disease  |h [elektronikus dokumentum] /  |c  Vécsei László 
260 |c 1995 
300 |a 35-41 
490 0 |a ARCHIVES OF GERONTOLOGY AND GERIATRICS  |v 21 
520 3 |a One of the most consistent neurochemical deficits in Alzheimer's disease is a reduction in cortical somatostatin concentrations. The probability of a predominant regulatory change is heightened by the finding that 90% of somatostatin positive nonpyramidal neurons are also positive for NADPH, and NADPH neurons are 'protected' in Alzheimer's disease and do not appear to be lost. The first evidence that somatostatin influences learning and memory processes in experimental animals was published more than a decade ago. These reports of somatostatin effects on cognitive functions in rats were later confirmed by several other studies. The somatostatin depleting substance cysteamine inhibited the learning and memory performance of rats in active and passive avoidance behavior tests. Post-mortem human studies suggest that although somatostatin concentration is reduced, the somatostatin receptors are less affected in the brain in Alzheimer's disease. These findings may be of importance for possible therapeutic approaches using somatostatin-receptor-influencing compounds. 
700 0 1 |a Klivényi Péter  |e aut 
856 4 0 |u http://publicatio.bibl.u-szeged.hu/10549/1/Vecsei_L._Somatostatin_AD._u.pdf  |z Dokumentum-elérés